These require local validation and implementation for clinical diagnostic purposes, similar to what has been previously done for several other actionable mutations in different tumor types (e.g., EGFR in lung cancer, BRAF in melanoma and lung cancer, etc.). The gene discussed is EGFR; the disease is lung cancer.